查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1641778

全球升糖素市场按产品类型、应用和分销管道划分 - 机会分析和产业预测，2024-2033 年

Glucagon Market By Product Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计升糖素市场规模在 2023 年将达到 3 亿美元，到 2033 年将达到 6 亿美元，2024 年至 2033 年的复合年增长率为 6.4%。

胰高血糖素市场-IMG1

升糖素是胰臟 α 细胞产生的肽激素。它在葡萄糖代谢中发挥重要作用，当血糖值血糖值过低时，它可以升高血糖，并维持体内的能源平衡。这种荷尔蒙主要作用于肝臟，促进肝醣的分解（肝醣分解）并刺激非碳水化合物来源产生葡萄糖（糖质新生）。升糖素可对抗胰岛素，降低血糖值。

全球糖尿病（尤其是第 1 型糖尿病）盛行率的惊人上升推动了对升糖素的需求，因为它是治疗严重低血糖的关键治疗方法。国际糖尿病联盟 (2023) 估计，全球有超过 5.4 亿成年人患有糖尿病，凸显了升糖素治疗的重要性。此外，医疗机构在低血糖管理方面的教育工作也促使升糖素製剂的采用率增加，尤其是对于发生严重低血糖事件风险较高的糖尿病患者。此外，老年人口的快速增加是全球市场的主要动力。随着世界人口老化，越来越多的人面临糖尿病和相关併发症的风险，从而推动了对升糖素产品的需求。世界卫生组织（WHO）2024年发布的一项研究显示，老年人口数量将从2020年的10亿增加到2030年的14亿。此外，到2050年，80岁及以上人口数量预计将达到4.26亿人。此外，升糖素不仅用于降血糖，而且越来越多地被用于诊断成像（例如放射学和内视镜检查）以放鬆消化道，扩大其市场范围。然而，升糖素疗法，尤其是较新的剂型如鼻内升糖素，价格昂贵，并且可能成为获得治疗的重大障碍，特别是对于低收入社区或缺乏足够医疗保险的患者而言。升糖素的使用，特别是在紧急情况下，通常需要医疗保健专业人员的指导才能正确使用，这可能会进一步限制其在无法立即获得医疗救助的情况下的使用。同时，预填充式注射器、自动注射器和鼻内升糖素製剂等技术创新使得给药变得更加容易，使患者和看护者能够更方便、更轻鬆地接受升糖素治疗。预计这些发展将为预测期内全球市场的扩张开闢新的途径。

全球升糖素产业分为类型、应用、分销管道和地区。根据类型，市场分为注射升糖素和鼻用升糖素。根据应用分为低血糖症和诊断支持。根据分销管道，分为医院药局、零售药局和网路药局。按地区分析，涵盖北美、欧洲、亚太、拉丁美洲以及中东和非洲。

主要发现

根据类型，注射胰高升糖素预计将在 2024 年至 2033 年期间占据市场主导地位。

根据应用，预计预测期内低血糖症领域在全球市场将呈现成长。

根据分销管道，医院药房部门预计在整个预测期内将以惊人的速度成长。

从地理上看，升糖素市场预计将在北美实现强劲成长。

此报告可自订。 （需支付额外费用和时间安排。）

  • 监管指南
  • 根据客户兴趣加入公司简介
  • 扩展公司简介列表
  • 赎回情况

目录

第 1 章 简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 重大投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会

第 4 章升糖素市场（依产品类型）

  • 市场概况
  • 注射用胰高升糖素
  • 鼻用胰高升糖素

第 5 章升糖素市场：按应用

  • 市场概况
  • 低血糖
  • 诊断辅助工具

第六章升糖素市场依通路划分

  • 市场概况
  • 医院药房
  • 零售药局
  • 网路药局

第 7 章升糖素市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国升糖素市场
    • 加拿大升糖素市场
    • 墨西哥的升糖素市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国升糖素市场
    • 德国升糖素市场
    • 义大利升糖素市场
    • 西班牙的升糖素市场
    • 英国升糖素市场
    • 其他欧洲国家升糖素市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国的升糖素市场
    • 日本升糖素市场
    • 印度升糖素市场
    • 韩国胰升糖素市场
    • 澳洲升糖素市场
    • 其他亚太地区胰高升糖素市场
  • 拉丁美洲、中东和非洲
    • 主要市场趋势和机会
    • 巴西的升糖素市场
    • 南非胰升糖素市场
    • 沙乌地阿拉伯的升糖素市场
    • 其他拉丁美洲、中东和非洲升糖素市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 前 10 家公司的产品映射
  • 竞争仪錶板
  • 竞争热图
  • 2023年主要企业的定位

第九章 公司简介

  • Novo Nordisk A/S
  • Fresenius SE And Co. KGaA
  • Amphastar Pharmaceuticals, Inc.
  • Xeris Biopharma Holdings, Inc.
  • ILS Inc
  • United Biotech（P）Limited
  • Zealand Pharma A/S
  • Taj Pharmaceuticals Limited
  • Eli Lilly And Company.
  • Pfizer Inc.
简介目录
Product Code: A324426

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Glucagon Market - IMG1

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Product Type

  • Injectable Glucagon
  • Nasal Glucagon

By Application

  • Hypoglycemia
  • Diagnostic Aid

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Novo Nordisk A/S
    • Fresenius SE & Co. KGaA
    • Amphastar Pharmaceuticals, Inc.
    • Xeris Biopharma Holdings, Inc.
    • ILS Inc
    • United Biotech (P) Limited
    • Zealand Pharma A/S
    • Taj Pharmaceuticals Limited
    • Eli Lilly and Company.
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Injectable Glucagon
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nasal Glucagon
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypoglycemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostic Aid
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Product Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Glucagon Market
      • 7.2.6.1. Market Size and Forecast, By Product Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Glucagon Market
      • 7.2.7.1. Market Size and Forecast, By Product Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Glucagon Market
      • 7.2.8.1. Market Size and Forecast, By Product Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Product Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Glucagon Market
      • 7.3.6.1. Market Size and Forecast, By Product Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Glucagon Market
      • 7.3.7.1. Market Size and Forecast, By Product Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Glucagon Market
      • 7.3.8.1. Market Size and Forecast, By Product Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Glucagon Market
      • 7.3.9.1. Market Size and Forecast, By Product Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Glucagon Market
      • 7.3.10.1. Market Size and Forecast, By Product Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest Of Europe Glucagon Market
      • 7.3.11.1. Market Size and Forecast, By Product Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Product Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Glucagon Market
      • 7.4.6.1. Market Size and Forecast, By Product Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Glucagon Market
      • 7.4.7.1. Market Size and Forecast, By Product Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Glucagon Market
      • 7.4.8.1. Market Size and Forecast, By Product Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Glucagon Market
      • 7.4.9.1. Market Size and Forecast, By Product Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Glucagon Market
      • 7.4.10.1. Market Size and Forecast, By Product Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Glucagon Market
      • 7.4.11.1. Market Size and Forecast, By Product Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Product Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Glucagon Market
      • 7.5.6.1. Market Size and Forecast, By Product Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Glucagon Market
      • 7.5.7.1. Market Size and Forecast, By Product Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Glucagon Market
      • 7.5.8.1. Market Size and Forecast, By Product Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Glucagon Market
      • 7.5.9.1. Market Size and Forecast, By Product Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping Of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novo Nordisk A/S
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Fresenius SE And Co. KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Amphastar Pharmaceuticals, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Xeris Biopharma Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. ILS Inc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. United Biotech (P) Limited
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Zealand Pharma A/S
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Taj Pharmaceuticals Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments